Trial intelligence / Profile preview

Asciminib versus investigator-selected TKI in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

2023-508838-33-00Phase 3Authorised

Sponsor

Novartis

Start

Oct 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

28